Verzenios
*Company:
Eli Lilly and Company (Ireland) LimitedStatus:
UpdatedLegal Category:
Product subject to restricted prescription (C)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 04 August 2025
File name
VERZENIOS SmPC_VE052_JUL25_IE-MT.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
Update to add ADR keratitis in frequence uncommon
Updated on 04 August 2025
File name
Verzenios_PIL_JUL25_VE053_IE-MT.pdf
Reasons for updating
- Change to section 4 - possible side effects
Free text change information supplied by the pharmaceutical company
Addition of ADR keratitis in frequence uncommon
Updated on 28 August 2024
File name
VERZENIOS SmPC_VE045_JUL24_IE-MT-NI clean.pdf
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to restricted prescription (C)
Updated on 04 July 2024
File name
Verzenios_PIL_JUN24_VE040_IE-MT-NI.pdf
Reasons for updating
- Change to section 4 - possible side effects
Updated on 04 July 2024
File name
VERZENIOS SmPC_VE039_JUN24_IE-MT-NI.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
Addition of Photopsia
Updated on 21 June 2024
File name
VERZENIOS SmPC_VE037_JUN24_IE-MT-NI.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to restricted prescription (C)
Updated on 21 June 2024
File name
Verzenios_PIL_JUN24_VE038_IE-MT-NI.pdf
Reasons for updating
- Change to section 4 - possible side effects
Updated on 07 March 2024
File name
VERZENIOS SmPC_VE033_NOV23_IE-MT-NI.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to restricted prescription (C)
Updated on 07 March 2024
File name
Verzenios_PIL_NOV23_VE034_IE-MT-NI.pdf
Reasons for updating
- New PIL for new product
Eli Lilly and Company (Ireland) Limited
 Limited.webp)
Address:
Lilly House, Basing View, Basingstoke, Hampshire, RG21 4FA, United KingdomMedical Information E-mail:
ukmedinfo@lilly.comTelephone:
+353 1 661 4377Website:
https://www.lilly.ie